BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer

SAN JOSE, Calif.: SAN JOSE, Calif., Dec. 15, 2021 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced a research collaboration agreement with the Peter MacCallum Cancer Centre (Peter Mac), a world...

Click to view original post